Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & DohmefiledCriticalMerck Sharp & Dohme
Publication of MY110795ApublicationCriticalpatent/MY110795A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
THE SULPHATE SALT OF N, N-DIMETHYL-2-[5[(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL) ETHYLAMINE IS A SELECTIVE AGONIST OF 5-HT1-LIKE RECEPTORS AND IS THEREFORE USEFUL IN THE TREATMENT OF CLINICAL CONDITIONS, IN PARTICULAR MIGRAINE AND ASSOCIATED DISORDERS, FOR WHICH A SELECTIVE AGONIST OF THESE RECEPTORS IS INDICATED.
MYPI94000764A1993-04-071994-03-30The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy
MY110795A
(en)
Use of imidazolin derivatives having alfa1l agonist effect for producing pharmaceutical compositions for treatment of incontinence, novel imidazolin derivatives and process for producing them
"PHARMACEUTICAL COMPOSITION CONTAINING CARBAZOLONE FOR THE TREATMENT OF MIGRAINE AND PSYCHOTIC DISORDERS AND RELATED METHOD OF PREPARATION AND APPLICATION".